Cancer immunotherapy has revolutionised cancer treatment, with immune checkpoint
blockade (ICB) therapy and adoptive cell therapy (ACT) increasingly becoming standard of …

Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The
current standard of care involves surgical resection (if possible) followed by concomitant …

Characterized by the expression of the critical transcription factor forkhead box protein P3,
regulatory T (Treg) cells are an essential part of the immune system, with a dual effect on the …

Simple Summary The relationship between the immune system and tumours is currently one
of the most studied topics in the field of cancer. Previously, it was thought that a tumour could …

T Regulatory cells (Tregs) can have both protective and pathological roles. They maintain
immune homeostasis and inhibit immune responses in various diseases, including cancer …

Glioblastoma is an immunosuppressive, fatal brain cancer that contains glioblastoma stem-
like cells (GSCs). Oncolytic herpes simplex virus (oHSV) selectively replicates in cancer …

Chimeric antigen receptor (CAR) T cell therapies have demonstrated remarkable efficacy for
the treatment of hematological malignancies. However, in patients with solid tumors …

In many aggressive cancers, such as glioblastoma multiforme, progression is enabled by
local immunosuppression driven by the accumulation of regulatory T cells (Treg) and …

The immunogenicity of cancer cells is an emerging determinant of anti‐cancer
immunotherapy. Beyond developing immunostimulatory regimens like dendritic cell‐based …

Recent years have seen significant efforts in understanding and modulating the immune
response in cancer. In this context, immunosuppressive cells, including regulatory T cells …